聚环氧琥珀酸及其复配物阻垢缓蚀性能的研究

针对火电厂循环冷却水水质研究了聚环氧琥珀酸(PESA)的阻垢性能,并同PASP、MA-AA、ATMP等阻垢剂的阻垢效果进行了比较.实验结果表明:PESA阻垢效果优良.比PASP、MA-AA阻垢效果更优,比ATMP阻垢效果稍差.针对凝汽器铜材质(HSn-70A)研究了单一聚环氧琥珀酸的缓蚀性能,开发了与之复配的复合配方,筛选出的最佳复配方案为10mg/L PESA+0.5 mg/L BTA+2mg/L Zn2++10mg/L葡萄糖酸钠,在此条件下铜的腐蚀率仅为0.0005mm/a.     

电厂循环水绿色水处理剂阻垢缓蚀性能的研究

采用静态阻垢法、静态挂片法、极化曲线法对绿色水处理剂聚天冬氨酸和聚环氧琥珀酸的缓蚀阻垢性能进行了研究,初步探讨了其缓蚀阻垢机理。通过静态阻垢实验结果可知,聚环氧琥珀酸的阻垢性能好于聚天冬氨酸(PASP),当聚环氧琥珀酸(PESA)和PASP质量浓度达到8mg/L之后阻垢率基本维持在一个水平;通过静态挂片实验结果可以看出PASP的最佳质量浓度为50mg/L,PESA的最佳质量浓度为40mg/L;通过极化曲线法可知PASP和PESA均属于抑制阳极型水处理剂。     

聚环氧琥珀酸用于高炉煤气洗涤水的阻垢分散

通过静态阻垢实验、Zeta电位测定实验、极化曲线测定实验,研究了聚环氧琥珀酸的阻垢、分散及缓蚀性能。重点对聚环氧琥珀酸的阻垢及分散性能作了讨论。实验结果表明了PESA阻垢、分散性能优良。将聚环氧琥珀酸(PESA)用于某钢铁厂高炉煤气洗涤水的阻垢分散,取得了令人满意的效果。     

环氧琥珀酸/丙烯酸/磺酸共聚物性能研究

采用静态阻垢法、静态挂片法、动态热水实验法,对实验室合成的环氧琥珀酸/丙烯酸/磺酸共聚物的缓蚀、阻垢及耐高温性能进行了研究。结果表明,该共聚物的阻垢性能优于乙二胺四甲叉膦酸五钠、水解马来酸酐;在加药量为20 mg/L时,其缓蚀性能优于丙烯酸共聚物、聚马来酸酐、聚环氧琥珀酸,并具有一定的耐高温性能。     

聚环氧琥珀酸与氨基三甲叉膦酸复配阻垢缓蚀性能研究

为了提高聚环氧琥珀酸(PESA)的缓蚀阻垢性能,将其与氨基三甲叉膦酸(ATMP)进行复配,研制了一种适合酸性条件新型缓蚀阻垢剂。通过静态阻垢实验、、塔菲尔极化曲线法、交流阻抗法及静态失重法研究了该缓蚀阻垢剂在酸性介质中的阻垢和缓蚀性能。实验结果表明;该缓蚀阻垢剂属于混合型缓蚀剂,在酸性介质中表现出了较好的阻垢和缓蚀效果。     

PESA/钨酸钠复配缓蚀阻垢剂协同性能研究

本文以PESA/钨酸钠作为复合试剂,考察了对电厂循环冷却水的缓蚀阻垢性能。实验结果表明,与TH-3100、PAA和HEDP相比,PESA对碳酸钙有较高的阻垢性能;钨酸钠单独使用时缓蚀性能较低,与阻垢剂复配使用后,其缓蚀率均上升;PESA∶钨酸钠最佳缓蚀阻垢配比为2∶1,当投加质量比分别为16mg/l和8mg/l时,复合试剂的阻垢率达到了96.3%,缓蚀率也达到了47.2%。与传统缓蚀阻垢剂相比,PESA/钨酸钠对环境的污染较少,本研究有一定应用价值!     

3种阻垢剂的阻垢性能测试及动力学研究

用静态阻垢法对聚天冬氨酸(PASP)、聚环氧琥珀酸(PESA)、马来酸/丙烯酸共聚物(MA/AA)的阻垢性能进行测试,对温度和浓度以及3种阻垢剂的动力学和最佳活化温度进行研究。研究结果表明:PASP、PESA分别在70、75℃对碳酸钙垢具有较高的阻垢率,但MA/AA的阻垢效果远大于PASP、PESA,MA/AA存在剂量效应。从3种阻垢剂的动力学研究和笼蔽效应来看,PASP和PESA为扩散控制,而MA/AA为活化控制。     

环保型阻垢分散剂的研制及其性能

以聚天冬氨酸(PASP)、聚环氧琥珀酸(PESA)和丙烯三羧酸.丙烯酸共聚物(AA-AA)为主体,开发出一种三元复配物阻垢分散剂,研究了不同质量配比复配物的阻垢性能、分散性能和生物降解性能.结果表明,当药剂用量为12mg/L时,质量比m(PASP):m(PESA):m(AA-AA)为1:1:2的三元复配物对CaCO_3的阻垢率为96.73%、分散氧化铁时的透光率仅为20.9%,28天时的生物降解率为76%.与国内外市场通用的磷系药剂相比,其阻垢分散性能优异,可替代现在使用的含磷或低磷产品.小型动态模拟试验结果表明在水质硬度为1056 mg/L时,其阻垢率仍达90%以上,该三元复配物是一种适用于高硬度水质的环保型阻垢分散剂.     

聚环氧琥珀酸的合成工艺优化与阻垢性能研究

以马来酸酐为原料,以钨酸钠为催化剂合成了聚环氧琥珀酸(PESA)。利用正交试验设计方法分别对环氧琥珀酸和聚环氧琥珀酸的合成工艺条件进行了优化。所得出的环氧琥珀酸的最佳合成工艺条件是:反应温度70℃、反应时间2 h、体系pH=7、m(MAH)∶m(H2O2)=1∶1.2;聚环氧琥珀酸的最佳合成工艺条件是:m(钨酸钠)∶m(环氧琥珀酸)=0.15∶1、聚合反应温度95℃、反应时间2 h。对于合成的PESA,通过静态阻垢试验结果表明,PESA在6 mg/L的投加量下就可达到接近100%的阻垢率,对高钙、高碱的苛刻水质有较好的容忍度,并可以适用于高温下的冷却水系统且可长时间停留。     

聚环氧琥珀酸的阻垢缓蚀性能研究

聚环氧琥珀酸（PESA）是一种新型的无磷有机阻垢缓蚀剂。通过鼓泡法和旋转挂片失重法对其阻垢性能和缓蚀性能进行了评价。结果表明,PESA比常用药剂HEDP、HPMA的阻垢性能好,但比PBTCA性能稍差;PESA也有一定的缓蚀性能,可以和其他的药剂复配生成低磷或无磷的缓蚀剂。     

缓蚀剂MA/TEA的合成及其性能研究

作者以马来酸酐(MA)、三乙醇胺(TEA)为原料,过硫酸铵为引发剂,合成二元共聚物MA/TEA缓蚀剂。实验结果表明,最佳合成条件为聚合温度70℃,聚合时间6h,当共聚物添加量6mg/L,硫脲添加量5mg/L时,缓蚀率85.83%,该二元共聚物缓蚀剂对碳钢挂片有较好的缓蚀效果。聚合物缓蚀剂在碳钢挂片表面形成致密的保护膜,使挂片与酸性介质隔离保护挂片。     

共聚物阻垢剂AA/APEY的合成及性能研究

以丙烯酸（AA）、大分子单体烯丙基聚氧乙烯基羧酸（APEY）为原料,利用自由基聚合反应在水相中制得聚醚型无磷共聚物阻垢剂AA/APEY.研究了共聚物单体质量配比、阻垢剂用量对AA-APEY阻碳酸钙、磷酸钙和硫酸钙性能的影响.结果表明AA/APEY具有优异的阻垢性能.     

AA/APES阻垢剂的合成及性能研究

以丙烯酸(AA)、烯丙氧基聚乙氧基硫酸铵(APES)为原料,过硫酸铵为引发体系,在水溶液中合成了AA/APES共聚物阻垢剂。考察了共聚物单体摩尔配比、阻垢剂用量对阻碳酸钙、磷酸钙垢率的影响,并与其它阻垢剂进行了比较。结果表明,AA/APES具有良好的阻碳酸钙和磷酸钙垢性能。     

新型绥蚀阻垢剂CA／HEDP／聚IA—SSA的性能研究

新型缓蚀阻垢剂柠檬酸(CA)/羟基乙叉二膦酸(HEDP)/聚衣康酸(IA)苯乙烯磺酸(SSA)有优良的抗腐蚀性能和阻垢性能,可用于循环冷却水系统。在70℃,ρ(Ca2+)<300mg/L,缓蚀阻垢剂100mg/L时缓蚀率和阻垢率(CaCO3)可达95%以上,其阻垢性能主要是由于晶格畸变及电荷排斥。电镜和AES分析表明其抗腐蚀性能是由于在金属表面形成很薄的保护膜(400～500),从而能有效抑制金属腐蚀。     

Novel and Potent Small Molecules against Melanoma Harboring BRAF Class I/II/III Mutants for Overcoming Drug Resistance

Melanoma accounts for the majority of skin cancer deaths. About 50% of all melanomas are associated with BRAF mutations. BRAF mutations are classified into three classes with regard to dependency on RAF dimerization and RAS signaling. The most frequently occurring class I BRAF V600 mutations are sensitive to vemurafenib whereas class II and class III mutants, non-V600 BRAF mutants are resistant to vemurafenib. Herein we report six pyrimido[4,5-d]pyrimidin-2-one derivatives possessing highly potent anti-proliferative activities on melanoma cells harboring BRAF class I/II/III mutants. Novel and most potent derivative, SIJ1777, possesses not only two-digit nanomolar potency but also 2 to 14-fold enhanced anti-proliferative activities compared with reference compound, GNF-7 against melanoma cells (SK-MEL-2, SK-MEL-28, A375, WM3670, WM3629). Moreover, SIJ1777 substantially inhibits the activation of MEK, ERK, and AKT and remarkably induces apoptosis and significantly blocks migration, invasion, and anchorage-independent growth of melanoma cells harboring BRAF class I/II/II mutations while both vemurafenib and PLX8394 have little to no effects on melanoma cells expressing BRAF class II/III mutations. Taken together, our six GNF-7 derivatives exhibit highly potent activities against melanoma cells harboring class I/II/III BRAF mutations compared with vemurafenib as well as PLX8394.     

含磷AA/AMPS共聚物的合成及阻垢性能研究

以水为溶剂，丙烯酸（AA），2-丙烯酰胺基-2-甲基丙磺酸（AMPS）和次磷酸钠为原料，合成了含磷AA/AMPS共聚物阻垢分散剂。探讨了单体配比，引发剂用量，反应温度等对共聚物阻垢性能的影响。得出了最佳合成条件：m(AA);m(AMPS)=75:25，引发剂与单体（AA和AMPS）的质量比为10%，反应时间4h，反应温度90℃，并采用静态实验法评价了共聚物的阻垢性能，结果表明，含磷AA/AMPS共聚物阻垢性能优良。     

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I

Translation of the synergy between the Siremadlin (MDM2 inhibitor) and Trametinib (MEK inhibitor) combination observed in vitro into in vivo synergistic efficacy in melanoma requires estimation of the interaction between these molecules at the pharmacokinetic (PK) and pharmacodynamic (PD) levels. The cytotoxicity of the Siremadlin and Trametinib combination was evaluated in vitro in melanoma A375 cells with MTS and RealTime-Glo assays. Analysis of the drug combination matrix was performed using Synergy and Synergyfinder packages. Calculated drug interaction metrics showed high synergy between Siremadlin and Trametinib: 23.12%, or a 7.48% increase of combined drug efficacy (concentration-independent parameter β from Synergy package analysis and concentration-dependent δ parameter from Synergyfinder analysis, respectively). In order to select the optimal PD interaction parameter which may translate observed in vitro synergy metrics into the in vivo setting, further PK/PD studies on cancer xenograft animal models coupled with PBPK/PD modelling are needed.     

酯交换抑制剂对PBT/PC共混体系性能的影响

通过对聚对苯二甲酸丁二酯／聚碳酸酯共混物的力学性能、热性能和微观结构的研究．考察了不同种类的酯交换抑制剂对其性能的影响．并进一步分析了酯交换抑制剂磷酸二氢钠的质量分数[ω（NaH2PO4)]对共混体系性能和结构的影响。结果表明,加入NaH2PO4,可以提高共混体系的简支梁缺口冲击强度、断裂伸长率及热稳定性;当ω（NaH2PO4)为0．75％,共混体系可以获得较好的综合性能。     

APP/层状硅酸盐填充UPR包覆层的耐烧蚀机理

将有机填料聚磷酸铵(APP)分别与层状硅酸盐类填料有机改性蒙脱土、滑石粉复配后填充UPR绝热包覆材料,通过氧乙炔烧蚀试验考察了复合材料的烧蚀性能.采用TG-DTG、SEM等研究有机-无机复配填料改性UPR包覆材料耐烧蚀性能的作用机理.结果表明,当APP与蒙脱土的质量比为20∶5,APP与滑石粉质量比为20∶30时,复合材料的耐烧蚀性能最佳,线烧蚀速率分别为0.317、0.363 mm/s.热分解试验600℃时,APP/有机改性蒙脱土/UPR的实际残留量比计算残留量增加8.2%,APP/滑石粉/UPR增加3.9%.烧蚀试验后APP/有机改性蒙脱土/UPR形成片层状残炭结构;APP/滑石粉/UPR生成较为松散的残炭.     

A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer

In recent years, three PARP inhibitors and three CDK4/6 inhibitors have been approved by the FDA for the treatment of recurrent ovarian cancer and advanced ER-positive breast cancer, respectively. However, the clinical benefits of the PARPi or CDK4/6i monotherapy are not as satisfied as expected and benefit only a fraction of patients. Current studies have shown therapeutic synergy for combinations of PARPi and CDK4/6i in breast and ovarian cancers with homologous recombination (HR) proficiency, which represents a new synthetic lethal strategy for treatment of these cancers regardless HR status. Thus, any compounds or strategies that can combine PARP and CDK4/6 inhibition will likely have great potential in improving clinic outcomes and in benefiting more patients. In this study, we developed a novel compound, ZC-22, that effectively inhibited both PARP and CDK4/6. This dual-targeting compound significantly inhibited breast and ovarian cancer cells by inducing cell cycle arrest and severe DNA damage both in vitro and in vivo. Interestingly, the efficacy of ZC-22 is even higher than the combination of PARPi Olaparib and CDK4/6i Abemaciclib in most breast and ovarian cancer cells, suggesting that it may be an effective alternative for the PARPi and CDK4/6i combination therapy. Moreover, ZC-22 sensitized breast and ovarian cancer cells to cisplatin treatment, a widely used chemotherapeutic agent. Altogether, our study has demonstrated the potency of a novel CDK4/6 and PARP dual inhibitor, which can potentially be developed into a monotherapy or combinatorial therapy with cisplatin for breast and ovarian cancer patients with HR proficiency.